3 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Recursion Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Clostridioides Difficile Trial of REC-3964 REC-3964 - Recurrent Clostridioides Difficile Infection | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 3 | 2024-10-14 | 2025-11-17 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation REC-4881 - AXIN1 Gene Mutation, APC Gene Mutation | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 18 | 2024-01-15 | 2026-02-23 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
Clostridium Infections (1) · Neoplasm Metastasis (1) · Neurofibromatosis 2 (1)
HDAC-42 (1)
United States (3) · United Kingdom (1)